NICE:2015年12月2型糖尿病管理指南更新6大要点

2015-12-04 catxa2016译 MedSci原创

NICE:2015年2型糖尿病更新指南6大要点。指南强调,将2型糖尿病患者的个体化治疗方案作为2型糖尿病管理的中心是至关重要的。例如指南建议2型糖尿病成年患者应参与决定个人HbA1c管理目标,HbA1c是反应2-3个月内血液中葡萄糖平均水平的指标。健康专家也建议个体化推荐碳水化合物摄入量、酒精摄入量和进餐模式。所有这些建议可改善2型糖尿病成年患者的预后,减少并发症,提高健康质量。 <p cl

2015年12月,NICE发布2型糖尿病指南更新(以下简称指南),共包括6大要点,专注于个性化健康管理助力成人2型糖尿病管理。指南更新关注于调整建议和个体化治疗,考虑患者合并症,重新评估患者需求。

指南强调了2型糖尿病成年患者结构化教育和/或患者家庭成员或护理人员帮助患者建立糖尿病自我管理的知识和技能的重要性。关于血糖管理的新建议明确指出:药物治疗的顺序以及进一步添加药物的时机,以期达到和维持目标血糖水平。指南的一个关键特点是提供一个算法帮助临床医生作出药物治疗决定。

指南包括管理血压和饮食建议的推荐建议,还包括并发症管理方针,包括糖尿病性眼病和勃起功能障碍,并指出关于糖尿病足的管理要点。

NICE首席执行官Andrew Dillon先生表示,在英国约有270万人患2型糖尿病。2型糖尿病长期并发症严重影响生活质量,但通过实施个体化的建议、支持和治疗,人们可以成功地管理2型糖尿病。本指南更新关注个体需求和偏好的重要性,把个体需求和偏好作为共同讨论和决策的核心。

遵循以下循证建议将使医疗卫生专业人员针对2型糖尿病患者建立个体化的治疗方案,以预防严重的糖尿病并发症发生。为了确保指南能与糖尿病治疗的新进展保持同步,NICE计划建立一个常设委员会定期更新糖尿病指南。”

2型糖尿病患者血糖浓度较高。这可能是因为患者身体不能产生足够的胰岛素控制血液中葡萄糖的含量,或者患者身体不能有效地使用胰岛素。目前诊断糖尿病的成年患者大约90%为2型糖尿病。如果不能有效的管理血糖水平,持续过高的血糖会引起组织损伤,导致失明、肾衰竭、足部溃疡可导致截肢、过早发作的心脏病、卒中和死亡。2型糖尿病在非洲人、加勒比海和南亚人群中更常见。

2型糖尿病指南建议包括:


1.根据2型糖尿病成年患者的需求和环境采用个性化的糖尿病管理方法,将患者的个人喜好、合并症、复方用药风险、长期干预的受益、预期寿命的减少等因素纳入决策过程。

2.每1-2个月测量血压,必要时使用抗高血压药物加强治疗,直到血压持续低于140/80mmHg。如果患者存在肾、眼或脑血管并发症,血压控制在130/80mmHg以下。

3.把饮食建议与个性化的糖尿病管理计划整合在一起,将其他方面的生活方式调整纳入其中,例如增加体力活动和减重。

4.推荐二甲双胍标准缓释片作为2型糖尿病成年患者初始药物治疗。

5.2型糖尿病成年患者,如果单一药物不能充分控制HbA1c水平,HbA1c水平≥58mmol/mol (7.5%):加强饮食建议、生活方式调整和坚持药物治疗,争取将HbA1c水平控制在53 mmol/mol (7.0%) 以下,必要时加强药物治疗。

6.2型糖尿病成年患者,测量HbA1c 水平:每3-6个月测量一次(根据个人需要),直到HbA1c 平稳,当药物治疗持续有效,血糖水平平稳时,可以每6个月测量一次HbA1c水平。

NICE糖尿病专家顾问和指南开发专家Amanda Adler博士认为这次更新2型糖尿病指南对于2型糖尿病患者和卫生专业人员是一个好消息,提供很多可用的治疗方法。指南全面包括了对2型糖尿病患者最好的治疗方案,考虑了药物的有效性、提高生活质量,并明智地利用NHS医疗资源。

指南鼓励所有患者健康饮食,积极进行体力活动。对于许多需要药物帮助管理糖尿病的2型糖尿病成年患者,指南详细说明了治疗方案的细节,总结了一系列治疗方案。”

NICE指南开发和内分泌学家Ian Lewin博士评论,指南强调,将2型糖尿病患者的个体化治疗方案作为2型糖尿病管理的中心是至关重要的。例如指南建议2型糖尿病成年患者应参与决定个人HbA1c管理目标,HbA1c是反应2-3个月内血液中葡萄糖平均水平的指标。健康专家也建议个体化推荐碳水化合物摄入量、酒精摄入量和进餐模式。所有这些建议可改善2型糖尿病成年患者的预后,减少并发症,提高健康质量。

原文出处:

1.Individualised care key to helping adults manage type 2diabetes in updated NICE guideline. MNT. 2 December 2015.

2.Type 2 diabetes in adults: managemen. NICE guidelines[NG28] Published date: December 2015.

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (10)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1804310, encodeId=ae5d180431094, content=<a href='/topic/show?id=598de675425' target=_blank style='color:#2F92EE;'>#糖尿病管理指南#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=76754, encryptionId=598de675425, topicName=糖尿病管理指南)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6eba113, createdName=xiaoyeshuang, createdTime=Tue Sep 20 09:05:00 CST 2016, time=2016-09-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1988225, encodeId=678a1988225f9, content=<a href='/topic/show?id=327e563967e' target=_blank style='color:#2F92EE;'>#指南更新#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=56396, encryptionId=327e563967e, topicName=指南更新)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=04ce158, createdName=lxg951, createdTime=Fri Oct 21 19:05:00 CST 2016, time=2016-10-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1931687, encodeId=db15193168e1e, content=<a href='/topic/show?id=1a76e6753b9' target=_blank style='color:#2F92EE;'>#糖尿病管理#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=76753, encryptionId=1a76e6753b9, topicName=糖尿病管理)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7ca4300, createdName=wodejia-dayu, createdTime=Sun Dec 27 16:05:00 CST 2015, time=2015-12-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1936290, encodeId=5c88193629080, content=<a href='/topic/show?id=daa1e60387b' target=_blank style='color:#2F92EE;'>#管理指南#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=76038, encryptionId=daa1e60387b, topicName=管理指南)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTIUEDhSibBFt8TicgFCCSBtW10SxVJicDpibTCucns8L1YaiaKpibWOkv8hYpJ0LeTVUH1Ab4sfica9bxiccA/132, createdBy=dd282500126, createdName=ms3830150583600765, createdTime=Fri Nov 18 14:05:00 CST 2016, time=2016-11-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=51833, encodeId=19915183389, content=赞, beContent=null, objectType=article, channel=null, level=null, likeNumber=21, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=fe261399236, createdName=xyfg98, createdTime=Mon Jan 04 18:32:00 CST 2016, time=2016-01-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=48934, encodeId=29844893450, content=好文章,值得收藏, beContent=null, objectType=article, channel=null, level=null, likeNumber=72, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=bc301610909, createdName=hixiaoluo, createdTime=Sun Dec 27 08:37:00 CST 2015, time=2015-12-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=45082, encodeId=df924508267, content=???, beContent=null, objectType=article, channel=null, level=null, likeNumber=132, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a63a1668977, createdName=李思思, createdTime=Mon Dec 07 15:20:00 CST 2015, time=2015-12-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=45083, encodeId=4689450834a, content=哈哈哈!, beContent=null, objectType=article, channel=null, level=null, likeNumber=114, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a63a1668977, createdName=李思思, createdTime=Mon Dec 07 15:20:00 CST 2015, time=2015-12-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=45084, encodeId=417945084b6, content=哈哈哈!, beContent=null, objectType=article, channel=null, level=null, likeNumber=99, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a63a1668977, createdName=李思思, createdTime=Mon Dec 07 15:20:00 CST 2015, time=2015-12-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1288919, encodeId=f183128891944, content=<a href='/topic/show?id=077112e9237' target=_blank style='color:#2F92EE;'>#NICE#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12792, encryptionId=077112e9237, topicName=NICE)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=743b215, createdName=fusion, createdTime=Sat Dec 05 17:05:00 CST 2015, time=2015-12-05, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=1804310, encodeId=ae5d180431094, content=<a href='/topic/show?id=598de675425' target=_blank style='color:#2F92EE;'>#糖尿病管理指南#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=76754, encryptionId=598de675425, topicName=糖尿病管理指南)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6eba113, createdName=xiaoyeshuang, createdTime=Tue Sep 20 09:05:00 CST 2016, time=2016-09-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1988225, encodeId=678a1988225f9, content=<a href='/topic/show?id=327e563967e' target=_blank style='color:#2F92EE;'>#指南更新#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=56396, encryptionId=327e563967e, topicName=指南更新)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=04ce158, createdName=lxg951, createdTime=Fri Oct 21 19:05:00 CST 2016, time=2016-10-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1931687, encodeId=db15193168e1e, content=<a href='/topic/show?id=1a76e6753b9' target=_blank style='color:#2F92EE;'>#糖尿病管理#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=76753, encryptionId=1a76e6753b9, topicName=糖尿病管理)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7ca4300, createdName=wodejia-dayu, createdTime=Sun Dec 27 16:05:00 CST 2015, time=2015-12-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1936290, encodeId=5c88193629080, content=<a href='/topic/show?id=daa1e60387b' target=_blank style='color:#2F92EE;'>#管理指南#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=76038, encryptionId=daa1e60387b, topicName=管理指南)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTIUEDhSibBFt8TicgFCCSBtW10SxVJicDpibTCucns8L1YaiaKpibWOkv8hYpJ0LeTVUH1Ab4sfica9bxiccA/132, createdBy=dd282500126, createdName=ms3830150583600765, createdTime=Fri Nov 18 14:05:00 CST 2016, time=2016-11-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=51833, encodeId=19915183389, content=赞, beContent=null, objectType=article, channel=null, level=null, likeNumber=21, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=fe261399236, createdName=xyfg98, createdTime=Mon Jan 04 18:32:00 CST 2016, time=2016-01-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=48934, encodeId=29844893450, content=好文章,值得收藏, beContent=null, objectType=article, channel=null, level=null, likeNumber=72, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=bc301610909, createdName=hixiaoluo, createdTime=Sun Dec 27 08:37:00 CST 2015, time=2015-12-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=45082, encodeId=df924508267, content=???, beContent=null, objectType=article, channel=null, level=null, likeNumber=132, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a63a1668977, createdName=李思思, createdTime=Mon Dec 07 15:20:00 CST 2015, time=2015-12-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=45083, encodeId=4689450834a, content=哈哈哈!, beContent=null, objectType=article, channel=null, level=null, likeNumber=114, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a63a1668977, createdName=李思思, createdTime=Mon Dec 07 15:20:00 CST 2015, time=2015-12-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=45084, encodeId=417945084b6, content=哈哈哈!, beContent=null, objectType=article, channel=null, level=null, likeNumber=99, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a63a1668977, createdName=李思思, createdTime=Mon Dec 07 15:20:00 CST 2015, time=2015-12-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1288919, encodeId=f183128891944, content=<a href='/topic/show?id=077112e9237' target=_blank style='color:#2F92EE;'>#NICE#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12792, encryptionId=077112e9237, topicName=NICE)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=743b215, createdName=fusion, createdTime=Sat Dec 05 17:05:00 CST 2015, time=2015-12-05, status=1, ipAttribution=)]
  3. [GetPortalCommentsPageByObjectIdResponse(id=1804310, encodeId=ae5d180431094, content=<a href='/topic/show?id=598de675425' target=_blank style='color:#2F92EE;'>#糖尿病管理指南#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=76754, encryptionId=598de675425, topicName=糖尿病管理指南)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6eba113, createdName=xiaoyeshuang, createdTime=Tue Sep 20 09:05:00 CST 2016, time=2016-09-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1988225, encodeId=678a1988225f9, content=<a href='/topic/show?id=327e563967e' target=_blank style='color:#2F92EE;'>#指南更新#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=56396, encryptionId=327e563967e, topicName=指南更新)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=04ce158, createdName=lxg951, createdTime=Fri Oct 21 19:05:00 CST 2016, time=2016-10-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1931687, encodeId=db15193168e1e, content=<a href='/topic/show?id=1a76e6753b9' target=_blank style='color:#2F92EE;'>#糖尿病管理#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=76753, encryptionId=1a76e6753b9, topicName=糖尿病管理)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7ca4300, createdName=wodejia-dayu, createdTime=Sun Dec 27 16:05:00 CST 2015, time=2015-12-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1936290, encodeId=5c88193629080, content=<a href='/topic/show?id=daa1e60387b' target=_blank style='color:#2F92EE;'>#管理指南#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=76038, encryptionId=daa1e60387b, topicName=管理指南)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTIUEDhSibBFt8TicgFCCSBtW10SxVJicDpibTCucns8L1YaiaKpibWOkv8hYpJ0LeTVUH1Ab4sfica9bxiccA/132, createdBy=dd282500126, createdName=ms3830150583600765, createdTime=Fri Nov 18 14:05:00 CST 2016, time=2016-11-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=51833, encodeId=19915183389, content=赞, beContent=null, objectType=article, channel=null, level=null, likeNumber=21, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=fe261399236, createdName=xyfg98, createdTime=Mon Jan 04 18:32:00 CST 2016, time=2016-01-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=48934, encodeId=29844893450, content=好文章,值得收藏, beContent=null, objectType=article, channel=null, level=null, likeNumber=72, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=bc301610909, createdName=hixiaoluo, createdTime=Sun Dec 27 08:37:00 CST 2015, time=2015-12-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=45082, encodeId=df924508267, content=???, beContent=null, objectType=article, channel=null, level=null, likeNumber=132, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a63a1668977, createdName=李思思, createdTime=Mon Dec 07 15:20:00 CST 2015, time=2015-12-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=45083, encodeId=4689450834a, content=哈哈哈!, beContent=null, objectType=article, channel=null, level=null, likeNumber=114, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a63a1668977, createdName=李思思, createdTime=Mon Dec 07 15:20:00 CST 2015, time=2015-12-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=45084, encodeId=417945084b6, content=哈哈哈!, beContent=null, objectType=article, channel=null, level=null, likeNumber=99, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a63a1668977, createdName=李思思, createdTime=Mon Dec 07 15:20:00 CST 2015, time=2015-12-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1288919, encodeId=f183128891944, content=<a href='/topic/show?id=077112e9237' target=_blank style='color:#2F92EE;'>#NICE#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12792, encryptionId=077112e9237, topicName=NICE)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=743b215, createdName=fusion, createdTime=Sat Dec 05 17:05:00 CST 2015, time=2015-12-05, status=1, ipAttribution=)]
  4. [GetPortalCommentsPageByObjectIdResponse(id=1804310, encodeId=ae5d180431094, content=<a href='/topic/show?id=598de675425' target=_blank style='color:#2F92EE;'>#糖尿病管理指南#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=76754, encryptionId=598de675425, topicName=糖尿病管理指南)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6eba113, createdName=xiaoyeshuang, createdTime=Tue Sep 20 09:05:00 CST 2016, time=2016-09-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1988225, encodeId=678a1988225f9, content=<a href='/topic/show?id=327e563967e' target=_blank style='color:#2F92EE;'>#指南更新#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=56396, encryptionId=327e563967e, topicName=指南更新)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=04ce158, createdName=lxg951, createdTime=Fri Oct 21 19:05:00 CST 2016, time=2016-10-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1931687, encodeId=db15193168e1e, content=<a href='/topic/show?id=1a76e6753b9' target=_blank style='color:#2F92EE;'>#糖尿病管理#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=76753, encryptionId=1a76e6753b9, topicName=糖尿病管理)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7ca4300, createdName=wodejia-dayu, createdTime=Sun Dec 27 16:05:00 CST 2015, time=2015-12-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1936290, encodeId=5c88193629080, content=<a href='/topic/show?id=daa1e60387b' target=_blank style='color:#2F92EE;'>#管理指南#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=76038, encryptionId=daa1e60387b, topicName=管理指南)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTIUEDhSibBFt8TicgFCCSBtW10SxVJicDpibTCucns8L1YaiaKpibWOkv8hYpJ0LeTVUH1Ab4sfica9bxiccA/132, createdBy=dd282500126, createdName=ms3830150583600765, createdTime=Fri Nov 18 14:05:00 CST 2016, time=2016-11-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=51833, encodeId=19915183389, content=赞, beContent=null, objectType=article, channel=null, level=null, likeNumber=21, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=fe261399236, createdName=xyfg98, createdTime=Mon Jan 04 18:32:00 CST 2016, time=2016-01-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=48934, encodeId=29844893450, content=好文章,值得收藏, beContent=null, objectType=article, channel=null, level=null, likeNumber=72, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=bc301610909, createdName=hixiaoluo, createdTime=Sun Dec 27 08:37:00 CST 2015, time=2015-12-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=45082, encodeId=df924508267, content=???, beContent=null, objectType=article, channel=null, level=null, likeNumber=132, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a63a1668977, createdName=李思思, createdTime=Mon Dec 07 15:20:00 CST 2015, time=2015-12-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=45083, encodeId=4689450834a, content=哈哈哈!, beContent=null, objectType=article, channel=null, level=null, likeNumber=114, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a63a1668977, createdName=李思思, createdTime=Mon Dec 07 15:20:00 CST 2015, time=2015-12-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=45084, encodeId=417945084b6, content=哈哈哈!, beContent=null, objectType=article, channel=null, level=null, likeNumber=99, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a63a1668977, createdName=李思思, createdTime=Mon Dec 07 15:20:00 CST 2015, time=2015-12-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1288919, encodeId=f183128891944, content=<a href='/topic/show?id=077112e9237' target=_blank style='color:#2F92EE;'>#NICE#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12792, encryptionId=077112e9237, topicName=NICE)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=743b215, createdName=fusion, createdTime=Sat Dec 05 17:05:00 CST 2015, time=2015-12-05, status=1, ipAttribution=)]
  5. [GetPortalCommentsPageByObjectIdResponse(id=1804310, encodeId=ae5d180431094, content=<a href='/topic/show?id=598de675425' target=_blank style='color:#2F92EE;'>#糖尿病管理指南#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=76754, encryptionId=598de675425, topicName=糖尿病管理指南)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6eba113, createdName=xiaoyeshuang, createdTime=Tue Sep 20 09:05:00 CST 2016, time=2016-09-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1988225, encodeId=678a1988225f9, content=<a href='/topic/show?id=327e563967e' target=_blank style='color:#2F92EE;'>#指南更新#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=56396, encryptionId=327e563967e, topicName=指南更新)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=04ce158, createdName=lxg951, createdTime=Fri Oct 21 19:05:00 CST 2016, time=2016-10-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1931687, encodeId=db15193168e1e, content=<a href='/topic/show?id=1a76e6753b9' target=_blank style='color:#2F92EE;'>#糖尿病管理#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=76753, encryptionId=1a76e6753b9, topicName=糖尿病管理)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7ca4300, createdName=wodejia-dayu, createdTime=Sun Dec 27 16:05:00 CST 2015, time=2015-12-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1936290, encodeId=5c88193629080, content=<a href='/topic/show?id=daa1e60387b' target=_blank style='color:#2F92EE;'>#管理指南#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=76038, encryptionId=daa1e60387b, topicName=管理指南)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTIUEDhSibBFt8TicgFCCSBtW10SxVJicDpibTCucns8L1YaiaKpibWOkv8hYpJ0LeTVUH1Ab4sfica9bxiccA/132, createdBy=dd282500126, createdName=ms3830150583600765, createdTime=Fri Nov 18 14:05:00 CST 2016, time=2016-11-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=51833, encodeId=19915183389, content=赞, beContent=null, objectType=article, channel=null, level=null, likeNumber=21, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=fe261399236, createdName=xyfg98, createdTime=Mon Jan 04 18:32:00 CST 2016, time=2016-01-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=48934, encodeId=29844893450, content=好文章,值得收藏, beContent=null, objectType=article, channel=null, level=null, likeNumber=72, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=bc301610909, createdName=hixiaoluo, createdTime=Sun Dec 27 08:37:00 CST 2015, time=2015-12-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=45082, encodeId=df924508267, content=???, beContent=null, objectType=article, channel=null, level=null, likeNumber=132, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a63a1668977, createdName=李思思, createdTime=Mon Dec 07 15:20:00 CST 2015, time=2015-12-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=45083, encodeId=4689450834a, content=哈哈哈!, beContent=null, objectType=article, channel=null, level=null, likeNumber=114, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a63a1668977, createdName=李思思, createdTime=Mon Dec 07 15:20:00 CST 2015, time=2015-12-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=45084, encodeId=417945084b6, content=哈哈哈!, beContent=null, objectType=article, channel=null, level=null, likeNumber=99, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a63a1668977, createdName=李思思, createdTime=Mon Dec 07 15:20:00 CST 2015, time=2015-12-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1288919, encodeId=f183128891944, content=<a href='/topic/show?id=077112e9237' target=_blank style='color:#2F92EE;'>#NICE#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12792, encryptionId=077112e9237, topicName=NICE)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=743b215, createdName=fusion, createdTime=Sat Dec 05 17:05:00 CST 2015, time=2015-12-05, status=1, ipAttribution=)]
    2016-01-04 xyfg98

    0

  6. [GetPortalCommentsPageByObjectIdResponse(id=1804310, encodeId=ae5d180431094, content=<a href='/topic/show?id=598de675425' target=_blank style='color:#2F92EE;'>#糖尿病管理指南#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=76754, encryptionId=598de675425, topicName=糖尿病管理指南)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6eba113, createdName=xiaoyeshuang, createdTime=Tue Sep 20 09:05:00 CST 2016, time=2016-09-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1988225, encodeId=678a1988225f9, content=<a href='/topic/show?id=327e563967e' target=_blank style='color:#2F92EE;'>#指南更新#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=56396, encryptionId=327e563967e, topicName=指南更新)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=04ce158, createdName=lxg951, createdTime=Fri Oct 21 19:05:00 CST 2016, time=2016-10-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1931687, encodeId=db15193168e1e, content=<a href='/topic/show?id=1a76e6753b9' target=_blank style='color:#2F92EE;'>#糖尿病管理#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=76753, encryptionId=1a76e6753b9, topicName=糖尿病管理)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7ca4300, createdName=wodejia-dayu, createdTime=Sun Dec 27 16:05:00 CST 2015, time=2015-12-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1936290, encodeId=5c88193629080, content=<a href='/topic/show?id=daa1e60387b' target=_blank style='color:#2F92EE;'>#管理指南#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=76038, encryptionId=daa1e60387b, topicName=管理指南)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTIUEDhSibBFt8TicgFCCSBtW10SxVJicDpibTCucns8L1YaiaKpibWOkv8hYpJ0LeTVUH1Ab4sfica9bxiccA/132, createdBy=dd282500126, createdName=ms3830150583600765, createdTime=Fri Nov 18 14:05:00 CST 2016, time=2016-11-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=51833, encodeId=19915183389, content=赞, beContent=null, objectType=article, channel=null, level=null, likeNumber=21, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=fe261399236, createdName=xyfg98, createdTime=Mon Jan 04 18:32:00 CST 2016, time=2016-01-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=48934, encodeId=29844893450, content=好文章,值得收藏, beContent=null, objectType=article, channel=null, level=null, likeNumber=72, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=bc301610909, createdName=hixiaoluo, createdTime=Sun Dec 27 08:37:00 CST 2015, time=2015-12-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=45082, encodeId=df924508267, content=???, beContent=null, objectType=article, channel=null, level=null, likeNumber=132, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a63a1668977, createdName=李思思, createdTime=Mon Dec 07 15:20:00 CST 2015, time=2015-12-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=45083, encodeId=4689450834a, content=哈哈哈!, beContent=null, objectType=article, channel=null, level=null, likeNumber=114, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a63a1668977, createdName=李思思, createdTime=Mon Dec 07 15:20:00 CST 2015, time=2015-12-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=45084, encodeId=417945084b6, content=哈哈哈!, beContent=null, objectType=article, channel=null, level=null, likeNumber=99, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a63a1668977, createdName=李思思, createdTime=Mon Dec 07 15:20:00 CST 2015, time=2015-12-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1288919, encodeId=f183128891944, content=<a href='/topic/show?id=077112e9237' target=_blank style='color:#2F92EE;'>#NICE#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12792, encryptionId=077112e9237, topicName=NICE)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=743b215, createdName=fusion, createdTime=Sat Dec 05 17:05:00 CST 2015, time=2015-12-05, status=1, ipAttribution=)]
    2015-12-27 hixiaoluo

    好文章,值得收藏

    0

  7. [GetPortalCommentsPageByObjectIdResponse(id=1804310, encodeId=ae5d180431094, content=<a href='/topic/show?id=598de675425' target=_blank style='color:#2F92EE;'>#糖尿病管理指南#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=76754, encryptionId=598de675425, topicName=糖尿病管理指南)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6eba113, createdName=xiaoyeshuang, createdTime=Tue Sep 20 09:05:00 CST 2016, time=2016-09-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1988225, encodeId=678a1988225f9, content=<a href='/topic/show?id=327e563967e' target=_blank style='color:#2F92EE;'>#指南更新#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=56396, encryptionId=327e563967e, topicName=指南更新)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=04ce158, createdName=lxg951, createdTime=Fri Oct 21 19:05:00 CST 2016, time=2016-10-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1931687, encodeId=db15193168e1e, content=<a href='/topic/show?id=1a76e6753b9' target=_blank style='color:#2F92EE;'>#糖尿病管理#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=76753, encryptionId=1a76e6753b9, topicName=糖尿病管理)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7ca4300, createdName=wodejia-dayu, createdTime=Sun Dec 27 16:05:00 CST 2015, time=2015-12-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1936290, encodeId=5c88193629080, content=<a href='/topic/show?id=daa1e60387b' target=_blank style='color:#2F92EE;'>#管理指南#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=76038, encryptionId=daa1e60387b, topicName=管理指南)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTIUEDhSibBFt8TicgFCCSBtW10SxVJicDpibTCucns8L1YaiaKpibWOkv8hYpJ0LeTVUH1Ab4sfica9bxiccA/132, createdBy=dd282500126, createdName=ms3830150583600765, createdTime=Fri Nov 18 14:05:00 CST 2016, time=2016-11-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=51833, encodeId=19915183389, content=赞, beContent=null, objectType=article, channel=null, level=null, likeNumber=21, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=fe261399236, createdName=xyfg98, createdTime=Mon Jan 04 18:32:00 CST 2016, time=2016-01-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=48934, encodeId=29844893450, content=好文章,值得收藏, beContent=null, objectType=article, channel=null, level=null, likeNumber=72, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=bc301610909, createdName=hixiaoluo, createdTime=Sun Dec 27 08:37:00 CST 2015, time=2015-12-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=45082, encodeId=df924508267, content=???, beContent=null, objectType=article, channel=null, level=null, likeNumber=132, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a63a1668977, createdName=李思思, createdTime=Mon Dec 07 15:20:00 CST 2015, time=2015-12-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=45083, encodeId=4689450834a, content=哈哈哈!, beContent=null, objectType=article, channel=null, level=null, likeNumber=114, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a63a1668977, createdName=李思思, createdTime=Mon Dec 07 15:20:00 CST 2015, time=2015-12-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=45084, encodeId=417945084b6, content=哈哈哈!, beContent=null, objectType=article, channel=null, level=null, likeNumber=99, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a63a1668977, createdName=李思思, createdTime=Mon Dec 07 15:20:00 CST 2015, time=2015-12-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1288919, encodeId=f183128891944, content=<a href='/topic/show?id=077112e9237' target=_blank style='color:#2F92EE;'>#NICE#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12792, encryptionId=077112e9237, topicName=NICE)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=743b215, createdName=fusion, createdTime=Sat Dec 05 17:05:00 CST 2015, time=2015-12-05, status=1, ipAttribution=)]
    2015-12-07 李思思

    ???

    0

  8. [GetPortalCommentsPageByObjectIdResponse(id=1804310, encodeId=ae5d180431094, content=<a href='/topic/show?id=598de675425' target=_blank style='color:#2F92EE;'>#糖尿病管理指南#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=76754, encryptionId=598de675425, topicName=糖尿病管理指南)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6eba113, createdName=xiaoyeshuang, createdTime=Tue Sep 20 09:05:00 CST 2016, time=2016-09-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1988225, encodeId=678a1988225f9, content=<a href='/topic/show?id=327e563967e' target=_blank style='color:#2F92EE;'>#指南更新#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=56396, encryptionId=327e563967e, topicName=指南更新)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=04ce158, createdName=lxg951, createdTime=Fri Oct 21 19:05:00 CST 2016, time=2016-10-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1931687, encodeId=db15193168e1e, content=<a href='/topic/show?id=1a76e6753b9' target=_blank style='color:#2F92EE;'>#糖尿病管理#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=76753, encryptionId=1a76e6753b9, topicName=糖尿病管理)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7ca4300, createdName=wodejia-dayu, createdTime=Sun Dec 27 16:05:00 CST 2015, time=2015-12-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1936290, encodeId=5c88193629080, content=<a href='/topic/show?id=daa1e60387b' target=_blank style='color:#2F92EE;'>#管理指南#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=76038, encryptionId=daa1e60387b, topicName=管理指南)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTIUEDhSibBFt8TicgFCCSBtW10SxVJicDpibTCucns8L1YaiaKpibWOkv8hYpJ0LeTVUH1Ab4sfica9bxiccA/132, createdBy=dd282500126, createdName=ms3830150583600765, createdTime=Fri Nov 18 14:05:00 CST 2016, time=2016-11-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=51833, encodeId=19915183389, content=赞, beContent=null, objectType=article, channel=null, level=null, likeNumber=21, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=fe261399236, createdName=xyfg98, createdTime=Mon Jan 04 18:32:00 CST 2016, time=2016-01-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=48934, encodeId=29844893450, content=好文章,值得收藏, beContent=null, objectType=article, channel=null, level=null, likeNumber=72, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=bc301610909, createdName=hixiaoluo, createdTime=Sun Dec 27 08:37:00 CST 2015, time=2015-12-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=45082, encodeId=df924508267, content=???, beContent=null, objectType=article, channel=null, level=null, likeNumber=132, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a63a1668977, createdName=李思思, createdTime=Mon Dec 07 15:20:00 CST 2015, time=2015-12-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=45083, encodeId=4689450834a, content=哈哈哈!, beContent=null, objectType=article, channel=null, level=null, likeNumber=114, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a63a1668977, createdName=李思思, createdTime=Mon Dec 07 15:20:00 CST 2015, time=2015-12-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=45084, encodeId=417945084b6, content=哈哈哈!, beContent=null, objectType=article, channel=null, level=null, likeNumber=99, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a63a1668977, createdName=李思思, createdTime=Mon Dec 07 15:20:00 CST 2015, time=2015-12-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1288919, encodeId=f183128891944, content=<a href='/topic/show?id=077112e9237' target=_blank style='color:#2F92EE;'>#NICE#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12792, encryptionId=077112e9237, topicName=NICE)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=743b215, createdName=fusion, createdTime=Sat Dec 05 17:05:00 CST 2015, time=2015-12-05, status=1, ipAttribution=)]
    2015-12-07 李思思

    哈哈哈!

    0

  9. [GetPortalCommentsPageByObjectIdResponse(id=1804310, encodeId=ae5d180431094, content=<a href='/topic/show?id=598de675425' target=_blank style='color:#2F92EE;'>#糖尿病管理指南#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=76754, encryptionId=598de675425, topicName=糖尿病管理指南)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6eba113, createdName=xiaoyeshuang, createdTime=Tue Sep 20 09:05:00 CST 2016, time=2016-09-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1988225, encodeId=678a1988225f9, content=<a href='/topic/show?id=327e563967e' target=_blank style='color:#2F92EE;'>#指南更新#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=56396, encryptionId=327e563967e, topicName=指南更新)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=04ce158, createdName=lxg951, createdTime=Fri Oct 21 19:05:00 CST 2016, time=2016-10-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1931687, encodeId=db15193168e1e, content=<a href='/topic/show?id=1a76e6753b9' target=_blank style='color:#2F92EE;'>#糖尿病管理#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=76753, encryptionId=1a76e6753b9, topicName=糖尿病管理)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7ca4300, createdName=wodejia-dayu, createdTime=Sun Dec 27 16:05:00 CST 2015, time=2015-12-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1936290, encodeId=5c88193629080, content=<a href='/topic/show?id=daa1e60387b' target=_blank style='color:#2F92EE;'>#管理指南#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=76038, encryptionId=daa1e60387b, topicName=管理指南)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTIUEDhSibBFt8TicgFCCSBtW10SxVJicDpibTCucns8L1YaiaKpibWOkv8hYpJ0LeTVUH1Ab4sfica9bxiccA/132, createdBy=dd282500126, createdName=ms3830150583600765, createdTime=Fri Nov 18 14:05:00 CST 2016, time=2016-11-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=51833, encodeId=19915183389, content=赞, beContent=null, objectType=article, channel=null, level=null, likeNumber=21, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=fe261399236, createdName=xyfg98, createdTime=Mon Jan 04 18:32:00 CST 2016, time=2016-01-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=48934, encodeId=29844893450, content=好文章,值得收藏, beContent=null, objectType=article, channel=null, level=null, likeNumber=72, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=bc301610909, createdName=hixiaoluo, createdTime=Sun Dec 27 08:37:00 CST 2015, time=2015-12-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=45082, encodeId=df924508267, content=???, beContent=null, objectType=article, channel=null, level=null, likeNumber=132, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a63a1668977, createdName=李思思, createdTime=Mon Dec 07 15:20:00 CST 2015, time=2015-12-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=45083, encodeId=4689450834a, content=哈哈哈!, beContent=null, objectType=article, channel=null, level=null, likeNumber=114, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a63a1668977, createdName=李思思, createdTime=Mon Dec 07 15:20:00 CST 2015, time=2015-12-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=45084, encodeId=417945084b6, content=哈哈哈!, beContent=null, objectType=article, channel=null, level=null, likeNumber=99, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a63a1668977, createdName=李思思, createdTime=Mon Dec 07 15:20:00 CST 2015, time=2015-12-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1288919, encodeId=f183128891944, content=<a href='/topic/show?id=077112e9237' target=_blank style='color:#2F92EE;'>#NICE#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12792, encryptionId=077112e9237, topicName=NICE)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=743b215, createdName=fusion, createdTime=Sat Dec 05 17:05:00 CST 2015, time=2015-12-05, status=1, ipAttribution=)]
    2015-12-07 李思思

    哈哈哈!

    0

  10. [GetPortalCommentsPageByObjectIdResponse(id=1804310, encodeId=ae5d180431094, content=<a href='/topic/show?id=598de675425' target=_blank style='color:#2F92EE;'>#糖尿病管理指南#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=76754, encryptionId=598de675425, topicName=糖尿病管理指南)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6eba113, createdName=xiaoyeshuang, createdTime=Tue Sep 20 09:05:00 CST 2016, time=2016-09-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1988225, encodeId=678a1988225f9, content=<a href='/topic/show?id=327e563967e' target=_blank style='color:#2F92EE;'>#指南更新#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=56396, encryptionId=327e563967e, topicName=指南更新)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=04ce158, createdName=lxg951, createdTime=Fri Oct 21 19:05:00 CST 2016, time=2016-10-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1931687, encodeId=db15193168e1e, content=<a href='/topic/show?id=1a76e6753b9' target=_blank style='color:#2F92EE;'>#糖尿病管理#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=76753, encryptionId=1a76e6753b9, topicName=糖尿病管理)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7ca4300, createdName=wodejia-dayu, createdTime=Sun Dec 27 16:05:00 CST 2015, time=2015-12-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1936290, encodeId=5c88193629080, content=<a href='/topic/show?id=daa1e60387b' target=_blank style='color:#2F92EE;'>#管理指南#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=76038, encryptionId=daa1e60387b, topicName=管理指南)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTIUEDhSibBFt8TicgFCCSBtW10SxVJicDpibTCucns8L1YaiaKpibWOkv8hYpJ0LeTVUH1Ab4sfica9bxiccA/132, createdBy=dd282500126, createdName=ms3830150583600765, createdTime=Fri Nov 18 14:05:00 CST 2016, time=2016-11-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=51833, encodeId=19915183389, content=赞, beContent=null, objectType=article, channel=null, level=null, likeNumber=21, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=fe261399236, createdName=xyfg98, createdTime=Mon Jan 04 18:32:00 CST 2016, time=2016-01-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=48934, encodeId=29844893450, content=好文章,值得收藏, beContent=null, objectType=article, channel=null, level=null, likeNumber=72, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=bc301610909, createdName=hixiaoluo, createdTime=Sun Dec 27 08:37:00 CST 2015, time=2015-12-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=45082, encodeId=df924508267, content=???, beContent=null, objectType=article, channel=null, level=null, likeNumber=132, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a63a1668977, createdName=李思思, createdTime=Mon Dec 07 15:20:00 CST 2015, time=2015-12-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=45083, encodeId=4689450834a, content=哈哈哈!, beContent=null, objectType=article, channel=null, level=null, likeNumber=114, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a63a1668977, createdName=李思思, createdTime=Mon Dec 07 15:20:00 CST 2015, time=2015-12-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=45084, encodeId=417945084b6, content=哈哈哈!, beContent=null, objectType=article, channel=null, level=null, likeNumber=99, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a63a1668977, createdName=李思思, createdTime=Mon Dec 07 15:20:00 CST 2015, time=2015-12-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1288919, encodeId=f183128891944, content=<a href='/topic/show?id=077112e9237' target=_blank style='color:#2F92EE;'>#NICE#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12792, encryptionId=077112e9237, topicName=NICE)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=743b215, createdName=fusion, createdTime=Sat Dec 05 17:05:00 CST 2015, time=2015-12-05, status=1, ipAttribution=)]
    2015-12-05 fusion

相关资讯

RSNA 2015:3D MRI技术或可改善糖尿病患者卒中风险的预测

新研究表明,使用3D MRI评估2型糖尿病患者颈动脉斑块内出血情况可以估计患者中风风险。斑块内出血是动脉粥样硬化疾病的一项指标,即使没有被发现颈动脉狭窄也可能发现斑块内出血。多伦多新宁研究所的Tishan Maraj在2015年北美放射学年会上对其发现进行了汇报。Dr Maraj和团队重点放在了糖尿病患者身上,因为糖尿病是卒中后预后不良的危险因素,且死亡风险明显增加。糖尿病是全球健康负担,预防并发

2015 IDF Atlas全球糖尿病报告第七版要点

根据IDF(International Diabetes Federation,国际糖尿病联合会)最新 Diabetes Atlas第七版,在世界范围内糖尿病成年患者大约有4.15亿名,全球每11名成年人就有1名患有糖尿病。

Diabetes Care: 2型糖尿病青少年女性患者不宜妊娠,患病期间后代出生缺陷比例高(TODAY研究)

尽管糖尿病特异信息推荐控制生育和避免妊娠,研究中仍有10%的受试者怀孕。2型糖尿病青少年患者怀孕,可能特别容易产出先天性畸形婴儿。2型糖尿病青少年患者怀孕产出先天性畸形婴儿比例较高的原因尚不清楚,但可能包括代谢控制较差和严重肥胖。 1.Birth Defect Rates High in Youth-Onset Type 2 Diabetes Pregnancies.Medscap

Diabetes Care:睾酮或可用于治疗2型糖尿病!

Diabetes Care最新文章表明,低水平睾酮的2型糖尿病男性使用睾酮治疗,效果甚好!雅各布斯大学医学和生物医学科学学院医学部门的 Dr. Paresh Dandona和同事早就知道低水平睾酮会明显降低胰岛素敏感性。在2004年他们发现了低水平睾酮与2型糖尿病的关系。6年后他们试图将其联系延伸到“肥胖”,对超过2000名男性的观察后发现,33%的参与者是2型糖尿病患者,不管是否肥胖,睾酮水平均

FASEB J:发现精神分裂症与糖尿病间存在联系的分子

我们很早就知道,精神疾病例如精神分裂症与2型糖尿病的高发有密切联系。发表在《美国实验生物学学会联合会杂志》一项新的研究发现,一个共同基因可能促成两种疾病的同时出现。本研究首次提出了证据表明DISC1基因也是一种新的基因,在胰腺β细胞生存和功能中起到意想不到的作用。它也首次提供了精神疾病患者与2型糖尿病之间的关系。为了证实这一发现,Bortell博士从基因层面操控一组小鼠来干扰破坏小鼠体内的胰腺β细